notebook
The Promise and Impact of the Next Generation of Weight Loss Drugs
19
Tags: Thyroid cancer, Bariatric surgery, Public health, Bimagrumab, Oncology, Endocrinology, Novartis, Obesity, Cardiology, European Medicines Agency, Gastroenterology, Cardiovascular disease, The Hungry Brain, Rimonabant, phentermine, Sibutramine, Liraglutide, David Macklin, Type 2 diabetes, Pancreatic cancer, Nutrition, Pfizer, Eli Lilly and Company, Semaglutide, Novo Nordisk, Food and Drug Administration, United States, Surgery, Medicine.
Comments
? comments